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ABSTRACT
Recent technological advances in cellular and molecular engineering have provided new insights into biology and enabled the design,
manufacturing, and manipulation of complex living systems. Here, we summarize the state of advances at the molecular, cellular, and multi-
cellular levels using experimental and computational tools. The areas of focus include intrinsically disordered proteins, synthetic proteins,
spatiotemporally dynamic extracellular matrices, organ-on-a-chip approaches, and computational modeling, which all have tremendous
potential for advancing fundamental and translational science. Perspectives on the current limitations and future directions are also
described, with the goal of stimulating interest to overcome these hurdles using multi-disciplinary approaches.
VC 2020 Author(s). All article content, except where otherwise noted, is licensed under a Creative Commons Attribution (CC BY) license (http://
creativecommons.org/licenses/by/4.0/). https://doi.org/10.1063/1.5129788
I. INTRODUCTION
Tissue and organ functions are largely dictated by complex
molecular and cellular interactions. Such interactions contribute to
homeostasis under physiological conditions and pathological disease
progression. In the advent of innovative technologies in cellular and
molecular bioengineering, the complex biological processes within tis-
sues and organs are being elucidated at greater resolution than ever
(Fig. 1). In addition, new insights and novel tools allow us to design
and reconstitute complex living systems. At the molecular level,
intrinsically disordered proteins (IDPs) and synthetic molecular
probes enable the understanding and detection of molecular assem-
blies and subcellular structures, as well as functional assessment.1 At
the single-cell and multi-cellular levels, inter-cellular communication
and the integration of chemical, physical, and biological cues derived
from the extracellular matrix (ECM) in a temporally and spatially
resolved manner become increasingly important. The biophysical
properties of the ECM, which modulate cellular behavior, include but
are not limited to stiffness, viscoelasticity, and viscoplasticity, along
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FIG. 1. Examples of engineering strategies in molecular, extracellular, and microphysiological systems. (a) Molecular engineering of a biosensor for membrane-type-1 matrix
metalloproteinase (MT1-MMP) activity based on changes in fluorescence emission. R-phycoerythrin (R-PE) fluorescence labeling of the intact biosensor allows energy transfer
from enhanced cyan fluorescent protein (ECFP) to R-PE. When activated, MT1-MMP cleaves the biosensor substrate sequence, thereby disrupting fluorescence resonance
energy transfer (FRET) and reducing the FRET/R-PE ratio. Reproduced with permission from Limsakul et al., Cell Chem. Biol. 25, 37 (2018). Copyright 2018 Elsevier.7 (b)
Schematic of the approach to tuning matrix plasticity in interpenetrating networks (IPNs) of alginate (blue) and reconstituted basement membrane matrix (green) by varying the
molecular weight of the alginate and ionic cross-linking. (c) By modulating the alginate molecular weight and degree of cross-linking, the permanent strain can be varied
between low plasticity (LP), medium plasticity (MP), and high plasticity (HP) IPNs. Permanent strain, which was measured by creep-recovery tests, was significantly higher in
HP IPNs, compared to MP and LP IPNs. For comparison, the permanent strain of polyacrylamide gels (PA) and silly putty are also provided. Statistically significant differences
are indicated [P< 0.01, P< 0.0001, analysis of variance (ANOVA)] and plasticity across the IPNs (####P< 0.0001, Spearman’s rank correlation). Reproduced with
permission from Wisdom et al., Nat. Commun. 9, 4144 (2018). Copyright 2018 Authors, licensed under a CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/).28 (d) An
example of a human heart-liver-on-a-chip for studying acetaminophen (APAP)-induced toxicity. Primary human hepatocytes and induced pluripotent stem cell (iPSC)-derived
cardiomyocytes were linked together in a dual-organoid system, and APAP was then introduced into the chip for 72 h. (e) Using an electrode-based biosensor, albumin from
hepatocytes could be quantified in the presence of APAP. The results show that albumin levels decreased in the presence of APAP, which is consistent with toxicity induced
hepatic impairment. The arrow depicts the time when APAP was introduced. Reproduced with permission from Zhang et al., Proc. Natl. Acad. Sci. U. S. A. 114, E2293 (2017).
Copyright 2017 National Academy of Science.54 (f) Schematic diagram depicts integrating systems and synthetic biology for morphogenetic engineering. Systems biology
applied to development can generate circuits for engineering cell-intrinsic and cell–cell interactions that can be used to engineer complex, multi-cellular behaviors such as mor-
phogenesis from pluripotent stem cells (PSCs). Reproduced with permission from Velazquez et al., Trends Biotechnol. 36, 415 (2018). Copyright 2018 Elsevier.2
APL Bioengineering PERSPECTIVE scitation.org/journal/apb
APL Bioeng. 4, 010906 (2020); doi: 10.1063/1.5129788 4, 010906-2
VC Author(s) 2020
with porosity, ligand patterning, spatial gradients, and three-
dimensional (3D) structures in nano-, micro-, and macro-scales. The
insights gained from molecular and cellular responses can be applied
toward organ-on-a-chip approaches to better understand tissue mor-
phogenesis, pathology, and cross talk between tissues and organs in
integrated systems. Finally, with recent advances in computational
modeling and bioinformatics, emerging multi-scale platforms that
incorporate intra-cellular regulatory networks and inter-cellular inter-
actions can be used to model complex multi-cellular processes.2 Here,
we overview the latest advances and future directions in bioengineer-
ing at the molecular, cellular, and multi-cellular levels. As cellular and
molecular bioengineering becomes increasingly more advanced, it is
hoped that the insights gained and technologies developed can have a
transformative impact in the fields of regenerative medicine, disease
modeling, and development. This perspective is a product of the dis-
cussions at the 2019 Cell and Molecular Bioengineering Conference in
Coronado, CA, USA, which highlights the breakthroughs and chal-
lenges in engineering biological complexity across length scales from
macromolecules to cells and tissues.
II. MOLECULAR SENSING AND CELLULAR SIGNALING
Molecular engineering has been widely explored as a robust
approach to generate molecular sensors to dissect cell signaling and
synthetic molecules for the assembly of multi-cellular structures and
smart materials. We will focus on molecular sensing and signaling here
and discuss extracellular molecular engineering in the later sections.
A. IDPs andmolecular engineering
Recent developments in molecular engineering strategies have
provided new insights into molecular mechanisms of cellular func-
tions. An emerging area of research is IDPs, which are proteins with
extensively disorganized protein structures.1,3 IDPs have been shown
to modulate phase transitions, leading to the condensation of nuclear
bodies and organelles that modulate cellular processes.1 The develop-
ment of light-controllable droplet assemblies based on phase transition
can reveal molecular insights connecting biophysical properties and
functional outcomes of molecular assemblies.4,5 Additionally, highly
sensitive and specific biosensors based on fluorescence resonance
energy transfer (FRET) and other signaling molecules are capable of
visualizing the effects of IDPs on force generation across specific pro-
teins such as focal adhesions in living cells. Future directions include
simultaneous monitoring of multiple signaling molecules in living
cells, the combination of signal sensing with functional actuation con-
trols, and the development of non-invasive biophysical control using
optical, electrical, and/or ultrasound technologies.
The integration of multi-scale computation and biophysical
experiments is primed to reveal the key factors that determine the
phase transition of IDPs.6 In the future, increasingly powerful compu-
tational algorithms and methods will become available to predict pro-
tein structures. Due to the plastic nature of IDP structures, traditional
molecular dynamics simulation and homology modeling are limited in
providing precise predictions of IDP conformations. The development
of deep learning and machine learning algorithms, as well as artificial
neural networks, should have significant impact under different physi-
ological conditions. In conjunction with high-throughput screening
approaches to integrate genetic library construction and deep sequenc-
ing technologies, it will become readily feasible to scan and characterize
a large number of protein mutants experimentally in a relatively fast
fashion. The iterative cross-comparison and adaptation between the
computational and experimental results and strategies should lead to
revolutionary progress in engineering new synthetic proteins, e.g.,
IDPs, and applying them to the imaging and controllable reprogram-
ming of cellular functions.
B. Synthetic protein engineering
The engineering of synthetic proteins, domains, and peptides is
increasingly needed for various biological and biomedical applications.
These engineered proteins can be used to study protein–protein inter-
actions and to develop biosensors for cellular imaging. For example,
directed evolution and high-throughput screening approaches have
been integrated to develop a monobody variant (PEbody) capable of
recognizing R-phycoerythrin (R-PE) that is fluorescent. Combined
with another fluorescent protein, this engineered PEbody with R-PE
can allow the tracking and visualizing of membrane bound matrix
metalloproteinase (MMP) in living cells [Fig. 1(a)].7 Single chain anti-
bodies (scFv), nanobodies, as well as other binding motifs, can also be
similarly developed for imaging. Protein engineering can further be
applied to develop therapeutic reagents. Indeed, numerous antibodies
and their derivatives have been engineered for therapeutic purposes.
For example, antibodies engineered with high specificity against
checkpoint inhibitory pathways of the T-cell protein, PD1, and cyto-
toxic T-lymphocyte associated protein-4 (CTLA4) have led to revolu-
tionary progress in cancer immunotherapy.8 Cytokines have also been
reengineered to enhance efficacy while minimizing non-specific toxic-
ity.9 The rational design of synthetic proteins requires the understand-
ing of the molecular structure-function relationship and advanced
computational simulation, and the selection and screening of designed
proteins will rely on high-throughput in vitro cellular or multi-cellular
systems.
With the rapid development of methods fostering library con-
struction, high-throughput screening, and directed evolution strate-
gies, overwhelmingly large numbers of different proteins/peptides can
be engineered. These protein/peptides can be applied toward emerging
areas such as engineering of synthetic organelles and cancer therapeu-
tics (Fig. 2).10,11 For experiment-based protein engineering, a key
remaining challenge is the efficient screening assay for desired func-
tions. Recent advances in computational analysis and algorithms have
made feasible the computational design of proteins. Based on the prin-
ciple of protein folding at the lowest free energy state,12 computational
algorithms and strategies have been successfully developed to find an
amino acid sequence capable of folding into a desired structure. It is
anticipated that the experimental assays based on directed evolution
and computational methods will increasingly converge for integrative
and novel approaches to allow the development of new generations of
proteins/peptides for fundamental research and for diagnostic and
therapeutic applications.
III. ENGINEERING THE NICHE: MOVING FROM SINGLE
CELLS TO MULTI-CELLULAR SYSTEMS
To move from a focus on molecular interactions within single
cells to a focus on multi-cellular structures-on-a-chip with the capacity
to function collectively as pseudo-organs, it is important to consider
both extrinsic inter-cellular interactions and the extracellular niche.
While the former may be self-explanatory or covered extensively
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elsewhere,13 the latter offers significant mechanobiological opportuni-
ties to control the multi-cellular behavior. The past decade provided
numerous systems with exquisite control over this niche in a variety of
contexts, but this originates with the observation that even the basic
cellular building blocks of a tissue rely on the topography,14 stiffness,15
porosity,16 degradability,17 and composition18 of ECM to dictate
behavior. In this section, we offer forward-looking observations of
how next generation materials should control cells and multi-cellular
structures. Namely, these include creating niches with spatial and tem-
poral control of ECM properties to guide the scale-up from cells to
organoids.
A. Next generation materials: Control in time and
space
While seminal observations a decade ago with individual cells on
gels created a paradigm shift that resulted in the creation of mecha-
nobiology as a field, so too will the next decade bring with it a series of
new mechanobiological observations with multi-cellular structures
and organoids. Cell–cell interactions are clearly important as stated
above, but we argue that the biggest opportunity in the next decade
for this field will be the development of increasingly dynamic engi-
neered systems to improve our control over organoid systems. While
not routine yet, leading work has shown that stem19 and cancer
cells20 can show “memory” of their former niche as their ECM soft-
ens or stiffens; reversible topography shows equally dynamic
responses in adult stem cells.21 Spatial changes can also play critical
roles, regardless of the specific matrix properties, using newer techni-
ques beyond conventional microcontact printing and soft lithogra-
phy methods. For example, spatial gradients of stiffness, porosity, or
ligand have become more common. We believe that the next decade
will include significant growth in complex systems using multiple
orthogonal patterns within a specific cue or single patterns of multi-
ple cues.22 Together these approaches may pose a more realistic
niche for questions of dynamic tissue-level behaviors associated with
disease modeling and development.
FIG. 2. Current and emerging areas of research in engineering at the molecular, cellular, and multi-cellular levels. At the molecular level, IDP conformational changes and syn-
thetic protein engineering can be applied toward the engineering of synthetic organelles and cancer therapeutics. At the cell-matrix level, innovations in spatiotemporal and
mechanical tuning of the ECM enable more accurate modeling of cell mechanics and tissue dynamics like wound healing. At the multi-cellular level, scalable mechanobiology
and higher order structures enable tissue engineering with increasing complexity and can be applied toward disease modeling. Reproduced with permission from Milles et al.,
Prog. Nucl. Magn. Reson. Spectrosc. 109, 79 (2018). Copyright 2018 Elsevier.3
APL Bioengineering PERSPECTIVE scitation.org/journal/apb
APL Bioeng. 4, 010906 (2020); doi: 10.1063/1.5129788 4, 010906-4
VC Author(s) 2020
B. Beyond elasticity: Viscoelasticity and viscoplasticity
Although the role of matrix stiffness, or elasticity, in regulating
cell behaviors is now increasingly well-understood, recent work has
revealed the additional impact of matrix viscoelasticity and viscoplas-
ticity in regulating cell behaviors. Many soft tissues and extracellular
matrices are viscoelastic, exhibiting stress relaxation in response to a
deformation, creep in response to a mechanical stress, or dissipating
mechanical energy imparted into the material.23,24 Sources of visco-
elasticity include the unbinding of weak, non-covalent bonds that link
the matrix components together and the dissipation of energy that
accompanies the movement of fluid through the matrix. Utilizing sub-
strates with tunable viscoelastic properties, recent studies have revealed
that the time-dependent relaxation or creep properties of the matrix
impact cell spreading, proliferation, matrix formation, and stem cell
differentiation in both two-dimensional (2D) and 3D culture sys-
tems.24–27 Mechanistic studies indicate that matrix viscoelasticity is
sensed by cells through integrin clustering, cytoskeletal tension, and, in
3D culture, gauging of resistance to cell volume expansion. Many vis-
coelastic matrices can also exhibit mechanical plasticity or irreversible
deformations in response to a mechanical stress or strain. For example,
interpenetrating networks (IPNs) of alginate and the reconstituted
basement membrane matrix with varying molecular weights result in
a range in permanent strain [Figs. 1(b) and 1(c)].28 Matrix mechanical
plasticity has been recently found to be a key regulator of regulate cell
migration, with cancer cells found to migrate through nanoporous
matrices, independent of proteases when the ECM exhibits sufficient
matrix mechanical plasticity.28 Thus, matrix viscoplasticity may be
related to the idea of confinement, with increased viscoplasticity corre-
sponding to decreased confinement.
Given that the role of matrix viscoelasticity and viscoplasticity in
mediating cell behaviors has only recently become appreciated, there
is an abundance of opportunities for new fundamental knowledge in
cell mechanics and key insights in applied areas such as wound healing
(Fig. 2).29,30 While an elastic modulus has been reported for many soft
tissues, the viscoelastic and viscoplastic properties of soft tissues at the
microscale, the length-scale relevant to cell mechanotransduction, are
unclear for many tissues. This characterization is critical to assessing
the relevance of these findings to specific tissues and biological pro-
cesses. In addition, while the mechanisms by which cells sense sub-
strate elasticity in 2D culture are now well known, those mediating
sensing of stress relaxation, particularly in 3D culture, remain unclear.
Molecular clutch based-models have been successful at predicting cell
responses to substrate elasticity and viscoelasticity in 2D culture, a
context in which cells sense mechanics through integrin-based adhe-
sions.31 However, in 3D culture, volume regulation and stretch acti-
vated channels have also been implicated in sensing matrix
viscoelasticity.32 Elucidating the pathways by which cells sense matrix
viscoelasticity, and how these interplay with the pathways that cells
use to sense matrix stiffness, fibrillarity, and biochemical cues, will be
an important task for the field in the coming decade (Fig. 2).
IV. MORPHOGENESIS ANDMICROPHYSIOLOGICAL
SYSTEMS
Moving from the cellular level to higher order structures, tissue
morphogenesis serves as a model system for engineering multi-cellular
structures and organs-on-a-chip. Here, we describe embryonic
development as an example of morphogenesis, along with the engi-
neering of organ-on-a-chip systems.
A. Cell and tissue biomechanics of morphogenesis
Embryonic development is a model of morphogenesis that can
reveal fundamental knowledge of cell behavior in response to mechan-
ical cues. For example, the mesendoderm of the Xenopus gastrula
undergoes directed migration as a collective unit, but the cues that
direct the spatiotemporal kinetics of migration are poorly understood.
By dissociating the mesendoderm into single cells, the effect of cell–cell
and cell–ECM interactions on cellular migration can be examined to
reveal underlying signaling mechanisms, including the recruitment of
keratin intermediate filaments at the rear and traction stresses at the
front of the cell being driven by actomyosin pulling on integrins.33 In
another model system, recent studies have shown that under suitable
culture conditions, human pluripotent stem cells can undergo intricate
morphogenetic events and self-organize to form patterned human
embryo-like structures in vitro.34–36 These synthetic human embryonic
tissues hold great promise for advancing our understanding of human
embryology and reproductive medicine. For example, the effect of spa-
tial patterning on neuroectoderm development can be studied in the
pluripotent stem cell model of development, in which geometric con-
finement can be shown to mimic early neurulation by the regionaliza-
tion of the neuroectoderm.37 However, there are still many aspects of
in vitro culture systems that warrant improvement, including the
determination of optimal chemical and mechanical properties of ECM
to support embryonic growth, the presentation of microenvironmental
factors in the niche, and the scale-up of the culture system for high-
throughput screening of culture conditions or drugs.
The insights gained from understanding embryonic morphogen-
esis can be applied in the future for the treatment of congenital
defects,38 which are a major cause of infant death.39 In particular, in
utero stem cell therapy has the potential to revolutionize the treatment
of congenital anomalies prior to birth. The fetal environment contains
numerous qualities that may facilitate stem cell therapy, including the
natural receptivity of the gestational environment to remodel and
regenerate fetal tissues by stem cells.40 Recently, it has been shown that
augmenting the in utero surgical repair of developmental defects with
stem cells could functionally cure neural tube defects and associated
motor function deficits at birth in large animal models.41,42
B. Scalable mechanobiology
It is now widely appreciated that the mechanics, dimensionality,
and other physical features of materials can strongly influence cell
behavior. However, experimental platforms commonly used to probe
these mechanobiological phenomena are challenging to reproducibly
synthesize, labor-intensive, and/or difficult to deploy in combinatorial
formats appropriate for screening. These characteristics limit the inte-
gration of mechanobiological concepts into the broader sphere of biol-
ogy and medicine. Thus, the field desperately needs
mechanobiological platforms that are scalable and parallelizable and
can be integrated into standard pipelines for discovery, diagnosis, and
screening. Early efforts to develop parallelized platforms for mecha-
nobiology focused on retrofitting standard multi-well plate paradigms
to accommodate engineered materials. This simple but powerful step
greatly facilitated automated microscopy and drug screening.43 As the
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field has progressed, the tools of microfabrication and robotic spotting
have been heavily leveraged to create microwell systems that allow
combinatorial deployment of various material properties, including
matrix stiffness, adhesivity, and enzymatic degradability.44
To reduce barriers to adoption, the new generation of platforms
must also be sufficiently robust and user-friendly to promote use
among biomedical and clinical scientists, even if this trades off to some
degree against technological innovation/sophistication. Because many
combinatorial mechanobiology systems require specialized equipment,
such as microfabrication facilities or robotic spotters, there remains a
need for platforms that can be fabricated using common laboratory
equipment. For example, gradient photopatterning of hyaluronic acid
hydrogels using orthogonal photochemistries and a simple UV light
source has recently been used to fabricate two-dimensional arrays of
matrix stiffness and adhesive ligand density on the same material.45
Enormous opportunity also exists to exploit organ-on-chip technolo-
gies for parallelized mechanobiology studies. This direction has been
foreshadowed by the first lung-on-chip device, where mechanical
stimulation of cells within the device strongly modulates responses to
inflammatory stimuli.46 Finally, the incorporation of multiple cell
types within a common platform remains a key challenge for the field.
For example, in microscale tumor models, it is important to include
not just the tumor cells but also associated stromal cells (e.g., fibro-
blasts, macrophages, and vasculature). There have been exciting first
steps in these directions toward modeling glioblastoma (GBM) tumors
using microfluidic strategies in which vessels are either allowed to self-
assemble in 3D matrices47 or are represented as needle-molded chan-
nels.48 Three-dimensional printing has also recently emerged as a
powerful strategy for integrating patient-derived tumor cells, vascular
cells, and matrix.49 Another emerging application of scalable technol-
ogy is the engineering of tissues with increasingly complex spatial
geometries and cell types for regenerative medicine.50
C. Organ-on-a-chip
Reproducing the human body in vitro is a dream that would
allow having human samples available for drug testing, disease studies
and corrections, and personalized medicine. By combining microflui-
dics with tissue engineering, numerous advances have been made in
the organ-on-a-chip field to create small-scale, biological structures
that recapitulate a specific organ function. Thus, these platforms have
already been developed for the kidney, liver, heart, breast, gut, and
blood vessels.51 Since they better mimic the hierarchical and physio-
logical conditions seen in vivo than conventional cultures in dishes,
they are especially attractive for assessing the toxicity of new drugs.
For example, a human heart-liver-on-a-chip system has been devel-
oped for studying acetaminophen (APAP)-induced toxicity using pri-
mary human hepatocytes and induced pluripotent stem cell (iPSC)-
derived cardiomyocytes [Fig. 1(d)].52
In the presence of APAP, liver toxicity could be functionally
detected by a reduction of albumin production [Fig. 1(e)]. However,
the combination of different modules with specific organs is required
to reproduce the physiological complexity seen in the human body
due to the interactions between different tissues and organs.53 If the
microfluidics allow easy connections between different modules to
build higher hierarchical systems, several challenges still remain before
reaching the ultimate goal of a human body on chip. First, a specific
organ should be engineered with human cells (rather than rodent
cells). These cells may come from biopsies, or human stem cells and
induced pluripotent stem cells can be used. Different methods for the
differentiation of stem cells toward specific lineage have been estab-
lished. Second, the structure, hierarchy, and functions of the organ
should be reproduced. Currently, to approach the complexity of native
organs, the technology uses organoid structures, which reproduce par-
tially the functionalities of the targeted organs. Then, two or several
organs that must be connected to obtain higher complexity in these
inter-relations will influx on the functionality and responses of each
organ. A common problem when culturing different tissues is to
define a universal culture medium able to support the growth and
maturation of different organs. One solution is the use of inner loops
of perfusion with specialized culture media to feed each specific organ
and a common outer loop of perfusion for connecting each organ
together. The development of sensors is also needed to monitor each
organ and their inter-relations. This analysis should be in real time
and continuous. To this end, Khademhosseini’s group has developed
electrochemical sensors with regenerative capabilities.54
A goal of organ-on-a-chip technology is to reproduce in vitro
specific structures of a tissue or organ to obtain optimal tissue func-
tionalities that are similar to those seen in vivo. However, these full
functionalities cannot be reached without inter-communication
between organs. To support the growth and maturation of cells to
obtain structural and hierarchical tissues, the combination of biomate-
rials and organ-on-a-chip may be advantageous. However, mimicking
the complexity of the ECM and reproducing a cellular niche are chal-
lenging. Therefore, the development of biomaterials also aims toward
more complexity and integration of several signals to cells. In the
building of complex structures, the bioprinting technology has arisen
due to its ability to deposit precisely cells and matrix in 3D. Apart
from the printer technology itself, the development of new bioinks
with adequate physical properties and good printability and supportive
properties for the growth and differentiation of cells are important
research areas. Currently, advancements in heterogeneous bioprinting
with different cells and different materials are needed to enhance the
complexity of the constructs obtained. Some attempts have been done
on the use of multi-materials as bioinks with promising results.55
Additionally, the engineering of thick tissues requires the integration
of vasculature for the delivery of oxygen, nutrients, and removal of
waste. It is anticipated that the next generation of organ-on-a-chip
platforms should integrate multi-materials, multi-cells, and vasculature
to obtain tissues with enhanced complexity and hierarchical structures
that are inter-related to each other, allowing a significant step toward
the development of a human-on-a-chip system for disease modeling
or drug screening applications (Fig. 2).56
V. COMPUTATIONAL ANALYSIS OF CELLULAR
NETWORKS
Computational simulations of biological processes have long been
used to explore mechanistic models with quantitative rigor, at resolu-
tions ranging from biochemical reactions to tissue-scale properties. In
general, computational simulations are used to determine the broad
plausibility of models or to test specific hypotheses by comparing simu-
lated data with experimental data.57 For example, computationally trac-
table whole-cell models have been created of host–pathogen interactions
from protein levels to cell–cell interactions.58 Such computational mod-
els can serve as a simulation tool for public access, use, and adaptation of
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other areas of research.59 Hybrid approaches that blend agent-based
modeling with pharmacokinetic and pharmacodynamic modeling are
powerful because they make simulations tractable while still retaining a
grounding in physical mechanisms. For example, this approach has been
used for studying tuberculosis to predict active vs latent infection and to
explore the vast design space of antibiotic treatment.60
An intriguing application of computational simulations, espe-
cially multi-scale platforms that incorporate both intra-cellular regula-
tory networks and cell–cell interactions, is to use them to guide efforts
to engineer complex multi-cellular phenomena such as morphogenesis
[Fig. 1(f)].2 However, a major limitation of cell-based simulations to
date is the lack of experimental data to constrain the initial models.
With the advent of single cell molecular profiling technologies, such as
mass cytometry,61 chromatin accessibility,62 and high throughput
transcriptomics,63–66 the landscape is rapidly changing. For example,
the Cahan laboratory recently developed a “cell typing” tool that deter-
mines the identity of a cell, as compared to a reference or annotated
dataset, using single-cell RNA-Seq data. They further applied this
approach to assess the fidelity of engineered cell populations, such as
those derived from direct conversion or directed differentiation.67 One
of the advances of this approach was that it is capable of performing
cell typing even when the reference dataset was generated using differ-
ent single cell RNA-Seq platforms or was from different species, open-
ing up the prospect of leveraging rapidly accumulating sets of murine
cell atlases to inform human single cell studies. Single-cell profiling
can also be used to understand the molecular basis of how macro-
phages respond to environmental stimuli from a wide array of possible
responses.68 One of the important advances of this work is the use of
single-cell secretion profiling in conjunction with single-cell RNA-Seq,
which links a critical functional readout to the molecular state of
tumor-associated macrophages and their response to immunotherapy.
In the broader field of single-cell analytics, there are several areas
that have received much attention and that we predict will feed into
cell and molecular bioengineering. First, the existing algorithms can
use single-cell RNA-Seq data to infer the position of each cell along a
trajectory that represents progression along a biological process, such
as differentiation or circadian rhythm.69 These trajectory inference
algorithms are useful because they allow for the application of time-
dependent analytical methods. For example, when applied to data
from developmental stages, these methods can reveal regulators of cell
fate decisions.70 Related to trajectory inference methods are algorithms
to use the ratio of spliced-to-unspliced transcript abundance to predict
the velocity or future transcriptional state of a cell.71 While the RNA
velocity approaches go beyond inferring trajectories by determining
directionality (for example, cells in cluster A are transitioning to clus-
ter B), it is a very new technique that requires a deeper exploration, its
limitations, and a fuller description of parameter customization.
Third, there are computational methods to integrate in situ with single
cell RNA-Seq data to infer the global transcriptional state and localiza-
tion.72,73 One of the benefits of these methods is that they enable the
inference of cell–cell interactions and help to characterize the influ-
ence of microanatomy on the expression state. While these methods
can be informative, they are likely to be supplanted in the near future
by better in situ sequencing technologies such as subcellular RNA-
Seq, 3D intact-tissue single-cell sequencing, and spatially resolved
single-cell sequencing.74–77 Finally, emerging methods can predict
ligand–receptor interactions from single-cell RNA-Seq data. Most of
these methods currently score putative interactions between clusters
of cells based on known ligand–receptor interactions.78–80 We antici-
pate that in the near future more advanced computational techniques
will yield more precise predictions by, for example, leveraging infor-
mation about downstream signaling pathway targets. With the con-
tinual advancement of technologies that generate genome-wide data
at a single-cell resolution, there are many opportunities for the devel-
opment of clever algorithms that can help to optimally translate these
big data into useful knowledge.
VI. CONCLUSION
In the past few decades, the convergence of advanced technolo-
gies and computational biology has enabled a greater understanding of
complex molecular, cellular, and extracellular interactions that regulate
the tissue function. In this Perspectives piece, we have discussed the
current state of the field, limitations in our understanding, and the
opportunities ahead to develop more complex systems that better
model tissue development, pathology, and regeneration. At the molec-
ular level, IDPs and synthetic protein engineering can be applied
toward applications such as imaging and modulation of cellular func-
tions, and the addition of machine learning will further improve our
fundamental understanding. At the multi-cellular level, organ-on-a-
chip approaches in the future will incorporate multiple cell types, vas-
cular networks, and more complex spatial geometries and bio-inks to
better mimic physiological tissue complexity. Technological advances
in computational modeling should enable more precise prediction of
ligand–receptor interactions or inference of global transcriptional pro-
files from single cell RNA-Seq data. We anticipate that other future
directions will include investigating the interactions of different cell
types within complex multi-cellular systems at the single-cell resolu-
tion by using single cell RNA sequencing and in situ high throughput
fluorescence in situ hybridization to map the cell phenotype and func-
tion. Other high-throughput technologies such as DNA microscopy
may also provide new insights into the relationship among the DNA
sequence, spatial organization, and cellular function. Additionally, the
convergence of next generation sequencing with drug screening may
enable the identification of new therapeutic treatments for a wide
range of diseases.81,82 Despite the current challenges, we anticipate
that molecular, cellular, and multi-cellular bioengineering approaches
will become increasingly important in many aspects of biomedical
research.
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